SCHEMBL30540586

SCHEMBL30540586

CCOC(=O)c1c(C#N)c(O)nc2c1CCC2(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
POLB P06746 3/20 0.44
ALDH1A1 P00352 10/20 0.37
KDM4E B2RXH2 7/20 0.37
HSD17B10 Q99714 4/20 0.37
HPGD P15428 4/20 0.37
L3MBTL1 Q9Y468 4/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
GAA P10253 3/20 0.34
CASP1 P29466 3/20 0.34
CASP7 P55210 2/20 0.34
MAPK10 P53779 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31115365 1.00 MAPT (0.44) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL4677981 0.77 KDM4E (0.55) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL30540486 0.77 KDM4E (0.55) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL25349781 0.77 KDM4E (0.55) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL30540660 0.74 MAPT (0.44) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL25349808 0.74 MAPT (0.44) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL2902560 0.68 KDM4E (0.45) MAPTALDH1A1KDM4EHPGDL3MBTL1
SCHEMBL21963952 0.68 KDM4E (0.50) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL30843856 0.66 ALDH1A1 (0.49) MAPTPOLBALDH1A1KDM4EHSD17B10
SCHEMBL26967888 0.66 ALDH1A1 (0.49) MAPTPOLBALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 US disclosed
EP-4476219-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene, Ltd. (KY) 2024-12-18 EP disclosed
WO-2023151642-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG MAPT 3757/4885POLB 2370/4885ALDH1A1 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.